Consequently, we present comprehensive evidence demonstrating that pyruvate could alleviate pathogenic features in DSS-induced murine colitis by inhibiting TNFα/NFκB signaling, maintaining intestinal mucosal barrier function, decreasing pro-inflammatory cytokines, and improving the diseased activity index. Here, TNF is linked to colitis.